Post-earnings recap
Reported
Mon, Feb 24, 2025
EPS actual
$-0.13
EPS est.
$-0.06
EPS surprise
-132.14%
1-day move
-9.99%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Biocryst Pharmaceuticals is facing challenges, as evidenced by the significant EPS miss. The stock reacted negatively, dropping nearly 10% in response to the lack of guidance and management's cautious outlook. Investors may be concerned about the company's ability to navigate current market conditions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | -132.14% |
| Revenue | N/A | N/A | N/A |
Management maintained a cautious tone during the earnings call, highlighting challenges in the market. They did not provide any forward guidance, indicating uncertainty about upcoming performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company expressed concerns about current market conditions impacting future performance.